Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-14
2007-08-14
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S320000, C544S321000
Reexamination Certificate
active
09787426
ABSTRACT:
A pyrimidone derivative represented by the formula (I) or a salts thereof:wherein R1represents an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group and the like; R2represents a hydrogen atom, hydroxyl group, an alkyl group, an alkenyl group and the like, R3represents a pyridyl group, and a medicament comprising said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as Alzheimer disease.
REFERENCES:
patent: 4166180 (1979-08-01), Kato et al.
patent: 4507302 (1985-03-01), Fast et al.
patent: 4619933 (1986-10-01), Stringfellow et al.
patent: 4725600 (1988-02-01), Takaya et al.
patent: 5612286 (1997-03-01), Mayer et al.
patent: 6096753 (2000-08-01), Spohr et al.
patent: 6107301 (2000-08-01), Aldrich et al.
patent: 6410729 (2002-06-01), Spohr et al.
patent: 6420385 (2002-07-01), Spohr et al.
patent: 6586441 (2003-07-01), Borroni et al.
patent: 6844335 (2005-01-01), Garcia et al.
patent: 2003/0187004 (2003-10-01), Garcia et al.
patent: 2005/0090490 (2005-04-01), Uehara et al.
patent: 2005/0130967 (2005-06-01), Uehara et al.
patent: 2005/0130998 (2005-06-01), Carcia et al.
patent: 2006/0252768 (2006-11-01), Watanabe et al.
patent: 0168262 (1986-01-01), None
patent: 0354179 (1989-07-01), None
patent: 1136482 (2001-09-01), None
patent: 218974 (1995-08-01), None
patent: P001698 (2001-04-01), None
patent: 49-035631 (1974-04-01), None
patent: 49-35632 (1974-04-01), None
patent: 49-035633 (1974-04-01), None
patent: 49-35634 (1974-04-01), None
patent: 49-035631 (1974-09-01), None
patent: 49-035633 (1974-09-01), None
patent: 52-71481 (1977-06-01), None
patent: 52/139085 (1977-11-01), None
patent: 6-239893 (1994-08-01), None
patent: 6-329551 (1994-11-01), None
patent: 93/11231 (1993-06-01), None
patent: 98/24782 (1998-06-01), None
patent: WO-98/24780 (1998-06-01), None
patent: 01/070728 (2001-09-01), None
patent: 01/070729 (2001-09-01), None
patent: 03/027080 (2003-04-01), None
patent: 03/037888 (2003-05-01), None
patent: 2004/055007 (2004-07-01), None
patent: 2004/085408 (2004-10-01), None
Ram, Vishnu J., “Chemotherapeutic agents . . . ”, Chemical Abstract, 1992, vol. 116, Abstract #59167.
Buehler et. al., “Pyrimidines series . . . ”, Chemical Abstract 1966, vol. 65, Abstract #90645.
Skulnick, H.I. et.al., “Pyrimidinones, . . . Interferon-Inducing Antviral Agents”, 1985, vol. 28, pp. 1864-1869.
Skulnick, H.I. et al., “Pyrimidinones, . . . Interferon-Inducing Antiviral Agents”, 1985, vol. 28, pp. 1864-1869.
Ulrich, Chapter 4: Crystallization, Kirk-Othmer Encyclopedia of Chemical Technology, Aug. 2002.
Vippagunta et al., Crystalline Solids, Advanced Drug Delivery Reviews, 48, pp. 3-26, 2001.
West, Solid Solutions, Solid State Chemistry and its applications, pp. 358 & 365, 1988.
Tani et al., CAPLUS Abstract 84:44112, 1976.
English Language Abstract of JP 6-239893, 1994.
English Language Abstract of JP 6-329551, 1994.
English Language Abstract of JP 52-71481, 1977.
Chemical Abstracts, vol. 100, No. 28, 1984, Columbus, Ohio, US, Abstract No. 174768e, M.R. Brana et al., “Reaction of N-(1-Oxido-4-Pyridylmethyl)-3,5-Dimethylbenzamide with Malononitrile in Acetic Anhydride”, p. 627; XP002127059.
Chemical Abstracts, vol. 84, No. 7, 1976, Columbus, Ohio, US, Abstract No. 44112b, Tani et al., “4-Hydroxy-Pyridylpyrimidine Derivatives”, p. 502, XP002127060.
Chemical Abstracts, vol. 82, No. 28, 1975, Columbus, Ohio, US, Abstract No. 170128n, Tani et al., “2,4,5-Trisubstituted-6-Pyridylpyrimidine Derivatives”, p. 555, XP002127061.
Chemical Abstracts, vol. 83, No. 28, 1975, Columbus, Ohio, US, Abstract No. 10127z, Tani et al., “5-Nitro-6-Pyridylpyrimidine Derivatives”, p. 853, XP002127062.
C.M. Wischik et al., “Isolation of a Fragment of Tau Derived from the core of the Paired Helical Filament of Alzheimer Disease”, Proc. Natl. Acad. Sci. USA, vol. 85, pp. 4506-4510 (1988).
Inge Grundke-Iqbal et al., “Abnormal Phosphorylation of the Microtubule-Associated Protien τ (Tau) in Alzheimer Cytoskeletal Pathology”, Proc. Natl. Acad. Sci. USA, vol. 83, pp. 4913-4917 (1986).
Koichi Ishiguro et al., “Tau Protein Kinase I Converts Normal Tau Protein into A68-like Component of Paired Helical Filaments”, The Journal of Biological Chemistry, vol. 267, No. 15, pp. 10897-10901 (1992).
Bruce A. Yankner et al., “Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides”, Science, vol. 250, pp. 279-282 (1990).
Akihiko Takashima et al., “Tau Protein Kinase I is Essential for Amyloid β-Protein-Induced Neurotoxicity”, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 7789-7793 (1993).
Von Hans-Joachim Kabbe, “Substituierte 4-Hydroxy- und 4-Amino-Pyrimidine”, Liebigs. Ann. Chem., vol. 701, pp. 144-149 (1967).
Harvey I. Skulnick et al., “Pyrimidinones. 1. 2-Amino-5-Halo-6-Aryl-4(3H)-Pyrimidinones. Interferon- Inducing Antiviral Agents”, J. Med. Chem., vol. 28, pp. 1864-1869 (1985).
G. Glenner et al., Biochemical and Biophysical Research Communications, vol. 120, No. 3, 1984, pp. 885-890.
C.L. Masters et al., The EMBO Journal, vol. 4, No. 11, 1985, pp. 2757-2763.
C.L. Masters et al., Proc. Natl. Acad. Sci. USA, vol. 82, Jun. 1985, pp. 4245-4249.
J. Kondo et al., Neuron, vol. 1, Nov. 1988, pp. 827-834.
R. Sherrington et al., Nature, vol. 375, Jun. 29, 1995, pp. 754-760.
E. Levy-Lahad et al., Science, vol. 269, Aug. 18, 1995, pp. 973-977.
E.I. Rogaev et al., Nature, vol. 376, Aug. 31, 1995, pp. 775-778.
D.R. Borchelt et al., Neuron, vol. 17, Nov. 1996, pp. 1005-1013.
T. Tomita et al., Proc. Natl. Acad. Sci. USA, vol. 94, Mar. 1997, pp. 2025-2030.
Sai-Shin Igaku, vol. 49, No. 9, 1994, pp. 1506-1512.
D.W. Dickson et al., Society for Neuroscience Abstracts, vol. 17, 1991, pp. 1445.
R. Siman et al., The Journal of Neuroscience, vol. 10, No. 7, Jul. 1990, pp. 2400-2411.
Shin-kei Shinpo, vol. 34, 1990, pp. 343-349.
Tanpaku-shitu Kaku-san Koso, vol. 41, 1996, pp. 1476-1483.
Tanpaku-shitu Kaku-san Koso, vol. 36, 1991, pp. 2-11.
Igaku no Ayumi, vol. 158, No. 9, Aug. 31, 1991, pp. 511-514.
Y. Ihara et al., J. Biochem., vol. 99, 1986, pp. 1807-1810.
I. Grundke-Iqbal et al., Proc. Natl. Acad. Sci. USA, vol. 83, Jul. 1986, pp. 4913-4917.
Seikagaku, vol. 64, No. 5, pp. 308-312.
K. Ishiguro et al., FEBS Lett., vol. 325, Jul. 1993, pp. 167-172.
H. Yinglin, Tetrahedron Letters, vol. 30, No. 39, 1989, pp. 5285-5286.
H. Yinglin, Synthesis, pp. 122-124, Feb. 1990.
R.L. Duncan Jr. et al., J. Med. Chem., vol. 13, No. 1, Jan. 1970, pp. 1-6.
D.L. Thai et al., J. Med. Chem., vol. 41, 1998, pp. 591-601.
Chemical Abstract 1992, vol. 116, Abstract # 59167.
Chemical Abstract 1966, vol. 65, Abstract # 90645.
U.S. Appl. No. 10/489,606 to Uehara et al., filed Sep. 20, 2002.
U.S. Appl. No. 10/489,607 to Uehara et al., filed Sep. 20, 2002.
Von Hans-Joachim Kabbe, “Substituierte 4-Hydroxy- und 4-Amino-Pyrimidine”, Liebigs. Ann. Chem., vol. 704, pp. 144-149 (1967).
U.S. Appl. No. 10/538,766, filed Dec. 12, 2003 to USUI et al.
Ando Ryoichi
Kawamoto Rie
Saito Ken-ichi
Shoda Aya
Watanabe Kazutoshi
Greenblum & Bernstein P.L.C.
Mitsubishi Chemical Corporation
Rao Deepak
LandOfFree
Pyrimidone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3875401